v3.25.1
Summary of Significant Accounting Policies - Summarizes The Effects of The Restatement By Financial-Statement Line Item Affected (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net sales $ 115,800 $ 135,143
Cost of sales 85,609 92,725
Gross profit 30,191 42,418
Operating expenses    
Selling, general and administrative (26,628) (29,469)
Research, product development and regulatory (5,682) (5,706)
Operating (loss) income (4,310) 6,091
Increase in accounts payable 22,966 2,366
Net cash used in operating activities (20,576) (36,107)
Borrowings under line of credit agreement 109,265 77,146
Net cash provided by financing activities $ 19,801 41,382
Previously Reported    
Operating expenses    
Increase in accounts payable   (3,951)
Net cash used in operating activities   (42,424)
Borrowings under line of credit agreement   83,463
Net cash provided by financing activities   47,699
Adjustments    
Operating expenses    
Increase in accounts payable   6,317
Net cash used in operating activities   6,317
Borrowings under line of credit agreement   (6,317)
Net cash provided by financing activities   (6,317)
As Restated    
Operating expenses    
Increase in accounts payable   2,366
Net cash used in operating activities   (36,107)
Borrowings under line of credit agreement   77,146
Net cash provided by financing activities   $ 41,382